Trending...
- Beyond Visionary Has Partnered With Heal America To Host INFORM Dallas
- Sea Island Writers Retreat and chromatic black™ Host Three Virtual Writing Workshops
- Kansas: Housing Trust Fund Board recommends 14 housing proposals
$360,000 grant to review safety and accuracy of Biosense® device aimed at DKA risk mitigation in patients using SGLTi drug class.
ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF. The two-year grant is aimed at testing the efficacy of the Biosense® handheld breath ketone monitor in persons with type 1 diabetes (T1D) during usual care with insulin and with the addition of a sodium glucose transporter inhibitor (SGLT2i) drug. Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award, will serve as the principal investigator.
Biosense® was launched in 2020 as the non-invasive option to capillary blood testing or urine testing for in-home biofeedback of fat oxidation levels based on nutrition and exercise. While metabolic disorders like type 2 diabetes (T2D) and obesity have protocols often seeking higher ketone levels, T1D patients can be at a considerable risk with elevated ketones, a problem potentially compounded by medications like SGLT2i if left unchecked. According to Dr. McGill, "Routine monitoring of ketones may alert patients to impeding ketosis and help to prevent episodes of ketoacidosis. Ketone monitoring should be easy, non-invasive, low-cost, and accessible for repeated use to be effective."
More on Missouriar
Biosense®, a class 1 designated breath ketone analyzer, will be tested for its ability to detect ketosis in persons with T1D during usual care and during usual care plus SGLTi therapy. Ultimately, the goal is to reduce the risk of diabetic ketoacidosis (DKA), which is increased when persons with T1D take an SGLT2i. This increased risk of life-threatening DKA has caused the FDA to withhold approval of SGLT2i in persons with T1D, despite proven benefits of drugs in this class for reduction in the risks of elevated glucose levels, progressive chronic kidney disease and hospitalizations for heart failure in persons with and without type 2 diabetes.
According to Jonathan Rosen, PhD, JDRF Associate Director of Research, "SGLT inhibitors are improving outcomes in glucose control, heart disease, and kidney disease in non-type 1 diabetes populations, but are rarely used in type 1 diabetes because they increase the risk of DKA. Development of ketone monitoring technologies like Biosense are a critical part of the strategy to enable safe, effective use of SGLT inhibitors in type 1 diabetes."
The JDRF funded research grant is awarded directly to Washington University School of Medicine at St. Louis with first patients targeted late summer.
About Readout Health
Readout Health is developing digital breath biomarker technologies for chronic disease prevention, management, and reversal. Readout's patented breath sampling technology isolates high concentration samples of breath compounds within handheld medical devices an supportive mobile apps. Targeting behavior modification through precision biofeedback, Biosense®, a Class 1 medical device, was launched as an FDA Class 1 medical device after a successful 2019 clinical trial, enabling pharma and academic researchers and clinicians to monitor patient dosing of therapeutic ketosis (area-under-the-curve) in several therapeutic areas, including metabolic, neurocognitive, and oncology. For more information, visit https://mybiosense.com.
More on Missouriar
About JDRF
JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit https://www.jdrf.org.
Media Contact: Press Team (314)-369-7477 [email protected]
SOURCE Readout Health
ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF. The two-year grant is aimed at testing the efficacy of the Biosense® handheld breath ketone monitor in persons with type 1 diabetes (T1D) during usual care with insulin and with the addition of a sodium glucose transporter inhibitor (SGLT2i) drug. Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award, will serve as the principal investigator.
Biosense® was launched in 2020 as the non-invasive option to capillary blood testing or urine testing for in-home biofeedback of fat oxidation levels based on nutrition and exercise. While metabolic disorders like type 2 diabetes (T2D) and obesity have protocols often seeking higher ketone levels, T1D patients can be at a considerable risk with elevated ketones, a problem potentially compounded by medications like SGLT2i if left unchecked. According to Dr. McGill, "Routine monitoring of ketones may alert patients to impeding ketosis and help to prevent episodes of ketoacidosis. Ketone monitoring should be easy, non-invasive, low-cost, and accessible for repeated use to be effective."
More on Missouriar
- City of Columbia announces fire chief finalists
- Diedra Harrison-Greenaway launches new book titled: The Blueprint: A Guide Towards Cannabis Business Ownership
- Core & Main Completes Acquisition of Inland Water Works Supply Co.
- Springfield: Novavax COVID-19 Vaccine Event will be held on Aug 18
- Evolytics Ranks #58 on Fortune's 2022 List of Best Small Workplaces™
Biosense®, a class 1 designated breath ketone analyzer, will be tested for its ability to detect ketosis in persons with T1D during usual care and during usual care plus SGLTi therapy. Ultimately, the goal is to reduce the risk of diabetic ketoacidosis (DKA), which is increased when persons with T1D take an SGLT2i. This increased risk of life-threatening DKA has caused the FDA to withhold approval of SGLT2i in persons with T1D, despite proven benefits of drugs in this class for reduction in the risks of elevated glucose levels, progressive chronic kidney disease and hospitalizations for heart failure in persons with and without type 2 diabetes.
According to Jonathan Rosen, PhD, JDRF Associate Director of Research, "SGLT inhibitors are improving outcomes in glucose control, heart disease, and kidney disease in non-type 1 diabetes populations, but are rarely used in type 1 diabetes because they increase the risk of DKA. Development of ketone monitoring technologies like Biosense are a critical part of the strategy to enable safe, effective use of SGLT inhibitors in type 1 diabetes."
The JDRF funded research grant is awarded directly to Washington University School of Medicine at St. Louis with first patients targeted late summer.
About Readout Health
Readout Health is developing digital breath biomarker technologies for chronic disease prevention, management, and reversal. Readout's patented breath sampling technology isolates high concentration samples of breath compounds within handheld medical devices an supportive mobile apps. Targeting behavior modification through precision biofeedback, Biosense®, a Class 1 medical device, was launched as an FDA Class 1 medical device after a successful 2019 clinical trial, enabling pharma and academic researchers and clinicians to monitor patient dosing of therapeutic ketosis (area-under-the-curve) in several therapeutic areas, including metabolic, neurocognitive, and oncology. For more information, visit https://mybiosense.com.
More on Missouriar
- Distinguished New York Trial Attorney and Author Donates Book Proceeds to NYU Cancer Research Center
- Congratulations to Meade Summers, Hilliker Corp. President, Selected as "2022 Best Bosses in STL"
- Treat Yourself Right This Summer With LA's Best Massage Therapy for Serious Pain Relief Near You!
- Springfield: Local Continuum of Care issues Notice of Funding Opportunity for homeless services projects
- DEKALB® Brand Announces Partnership As Official Corn Seed of MLB at Field of Dreams
About JDRF
JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit https://www.jdrf.org.
Media Contact: Press Team (314)-369-7477 [email protected]
SOURCE Readout Health
Filed Under: Business
0 Comments
Latest on Missouriar
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
- Nino X Man releases Hip-Hop Compilation titled "662 the Truth" with No Limit Forever East
- St. Louis Municipal Courts Dismisses Backlog of Low-Level Cases as City of St. Louis Announces Date for Warrant Reset Day, Second Chance Job Fair
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
- Missouri American Water Completes Acquisition of Eureka Water and Wastewater Systems, Plans for Pipeline Construction
- Kansas: Audit of the Short Term Rental Program Initiated
- Kansas: Community Policing and Prevention Fund Audit Initiated
- Kansas: City Auditor's Office Annual Report for Fiscal Year 2022
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- Columbia: Interested parties meeting for Greek Town sidewalk improvement project to be held Aug. 10
- Columbia: Lane closure due to road work scheduled for Aug. 8-11 on East Brown School Road
- Ann Marr Joins Board of Directors of Cass Information Systems, Inc.
- Berkeley Lights and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of a Patient-Derived T cell Receptor Sequence Against a Cancer Neoantigen
- Caleres to Announce Second Quarter 2022 Results on August 23
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- MEDIA ALERT: Press conference Thursday to report out Prosper Springfield progress
- Multi-Agency Resource Center for Flood Survivors Announced for City of St. Louis
- Interested parties meeting for Phase 2 of new terminal project at Columbia Regional Airport scheduled for Aug. 10
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- New Jewish Theatre Presents World Premiere of "The Bee Play" September 8-25